Speed saves lives. Evidence saves time.
Pharm·ology quantifies decisions in drug development — target product profile, clinical and regulatory strategy, product development plan, risk management and probability of success — against the evidence that already exists.
Every day a medicine is late is a day the patients who need it do not have it. Most of that delay is not science. It is the weeks spent assembling evidence.
This is why Pharm·ology was founded by a former FDA reviewer and pharma portfolio executive — to quantify drug development decisions that matter (meet the Founder).
THE PROBLEM
The answer usually already exists. It is just unreachable.
- Somebody has run a clinical trial similar to yours.
- Somebody has asked your regulatory question in a meeting.
- Somebody has already submitted an application for regulatory approval for your disease of interest.
None of it is secret. All of it is public. But almost none of it is reachable before the decision is due.
WHAT WE DO
Six decisions, quantified.
"Totality of evidence" is a phrase regulators use to indicate they looked at all available data. We built a platform that lets you do the same thing before they do.
Pharm·ology turns the public record into answers to the six questions that actually move a development program.
Target product profile
What you have to beat, by how much, and on which endpoint — benchmarked against every approved label and every phase 2/3 competitor in your indication, attribute by attribute.
Clinical program strategy
A trial program sized by what comparable trials actually did: enrollment, sites, recruitment rate, treatment duration, dropout. Assumptions you can defend line by line instead of negotiate.
Regulatory strategy
What the agency has already told sponsors in your position, quoted from the meeting minutes and review documents. Including the times they
said no.
Product development plan
Phase durations, white space between phases, first-human-dose to submission — measured across the programs that have run in your therapeutic area, not assumed from a template.
Risk management
Where comparable programs failed, and what the regulator flagged before they did. Your program’s gaps by phase — timelines, endpoints, safety, guidance adherence — named early enough to close.
Probability of success
Industry PoS benchmarks describe a class, not your asset. We adjust them with program-specific evidence — precedent, design, regulatory history — so the number in your model survives the board’s questions.
HOW WE DO IT
Every clinical trial. Every regulatory guidance. Every regulatory meeting. Every regulatory review. Every drug approval. One question away.
QD [Quantify Decisions] is the drug development platform that turns the entire clinical and regulatory public record into quantified answers.
Ask your AI agent in plain language or work in the web application. Every figure it returns carries the table, record and source it came from, so any number on a board slide can be traced back to the regulatory document or the trial registry entry it came from.
WHO IT IS FOR
Built for the people who have to decide.
Biotech CEOs and CMO/CDOs setting a development path with one shot at getting it right.
Pharma portfolio and project leadership deciding what to fund, kill or accelerate.
Regulatory and clinical leads preparing for an agency meeting or a submission.
VC and investors who need a program assessed on precedent rather than on the deck.
Pharm·ology - The Science of Drug Development
Pharm·ology ApS · contact@pharmology.dk · CVR 45557898
THE WHY